Oct, 2020

U.S.A.
News / Therapeutic Area News
New Roxadustat Data in Anemia of Chronic Kidney Disease to be Released at ASN Kidney Week 2020 Reimagined
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, PhD, "Astellas") today announced that in collaboration with FibroGen and AstraZeneca, 42 roxadustat abstracts will be presented...
Read More

Sep, 2020

U.S.A.
News / Therapeutic Area News
Astellas' Real-World Evidence Studies Provide Further Insight into Negative Impacts of Vasomotor Symptoms (VMS) Associated with Menopause
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced findings from two Real-World Evidence (RWE) studies and a qualitative sleep survey that...
Read More
U.S.A.
News / Therapeutic Area News
Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that a phase 3 trial of PADCEV® (enfortumab...
Read More

Jun, 2020

U.S.A.
News / Therapeutic Area News
Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced results from the Phase 3 DOLOMITES study, evaluating the efficacy and safety of roxadustat...
Read More

May, 2020

U.S.A.
News / Therapeutic Area News
Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") have announced final results from the overall survival (OS) analysis of the Phase...
Read More